BUZZ-PREVIEW: Merck expected to report Q1 EPS, revenue increase

Reuters04-25

** Merck & Co shares up 0.2% ahead of quarterly report due out before market open on Thursday

** Wall St sees MRK reporting adj. EPS of $1.88 vs $1.40 year-ago on revenue of $15.196, which would be up ~4.9% y/y, according to the latest data from LSEG

** In last 8 quarters MRK beat consensus estimate for EPS and revenue every time

** In early February Merck reported Q4 results that beat expectations on strong sales of its cancer immunotherapy Keytruda - the world's top-selling prescription medicine - but said it was in the market for acquisitions as Keytruda ages

** YTD shares in MRK up ~17% vs a ~3% gain for the S&P 500 health index and a ~2% increase for the Dow Industrial average

** MRK last traded at $127.26 vs median PT of $139, according to LSEG, which shows 27 total analyst ratings; 8 'strong buy,' 16 'buy' and 3 'hold' ratings

(Reporting By Sinéad Carew)

((sinead.carew@thomsonreuters.com; +13322191897;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2430462963?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-25 02:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2430462963","market":"us","top_or_hot":-1,"title":"BUZZ-PREVIEW: Merck expected to report Q1 EPS, revenue increase","media":"Reuters","content":"<html><body><p>** Merck &amp; Co    shares up 0.2% ahead of quarterly report due out before market open on Thursday</p><p>   ** Wall St sees MRK reporting adj. EPS of $1.88 vs $1.40 year-ago on revenue of $15.196, which would be up ~4.9% y/y, according to the latest data from LSEG</p><p>   ** In last 8 quarters MRK beat consensus estimate for EPS and revenue every time</p><p>   ** In early February Merck reported Q4 results that beat expectations on strong sales of its cancer immunotherapy Keytruda - the world's top-selling prescription medicine - but said it was in the market for acquisitions as Keytruda ages </p><p>   ** YTD shares in MRK up ~17% vs a ~3% gain for the S&amp;P 500 health index    and a ~2% increase for the Dow Industrial average   </p><p>   ** MRK last traded at $127.26 vs median PT of $139, according to LSEG, which shows 27 total analyst ratings; 8 'strong buy,' 16 'buy' and 3 'hold' ratings</p><p> (Reporting By Sinéad Carew)</p><p>((sinead.carew@thomsonreuters.com; +13322191897;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-PREVIEW: Merck expected to report Q1 EPS, revenue increase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-PREVIEW: Merck expected to report Q1 EPS, revenue increase\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-25 02:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>** Merck & Co    shares up 0.2% ahead of quarterly report due out before market open on Thursday   ** Wall St sees MRK reporting adj. EPS of $1.88 vs $1.40 year-ago on revenue of $15.196, which would ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":".DJI","symbol_name":"道琼斯","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2430462963","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2430462963","pubTimestamp":1713983661,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"** Merck & Co    shares up 0.2% ahead of quarterly report due out before market open on Thursday   ** Wall St sees MRK reporting adj. EPS of $1.88 vs $1.40 year-ago on revenue of $15.196, which would ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{".DJI":"道琼斯","BUZZ":"VanEck Social Sentiment ETF","MRK":"默沙东"},"translate_title":"嗡嗡声预览：默克公司预计将报告第一季度每股收益，收入增加","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BUZZ":1,"MRK":1,".DJI":0.9},"content_text":"** Merck & Co    shares up 0.2% ahead of quarterly report due out before market open on Thursday   ** Wall St sees MRK reporting adj. EPS of $1.88 vs $1.40 year-ago on revenue of $15.196, which would be up ~4.9% y/y, according to the latest data from LSEG   ** In last 8 quarters MRK beat consensus estimate for EPS and revenue every time   ** In early February Merck reported Q4 results that beat expectations on strong sales of its cancer immunotherapy Keytruda - the world's top-selling prescription medicine - but said it was in the market for acquisitions as Keytruda ages    ** YTD shares in MRK up ~17% vs a ~3% gain for the S&P 500 health index    and a ~2% increase for the Dow Industrial average      ** MRK last traded at $127.26 vs median PT of $139, according to LSEG, which shows 27 total analyst ratings; 8 'strong buy,' 16 'buy' and 3 'hold' ratings (Reporting By Sinéad Carew)((sinead.carew@thomsonreuters.com; +13322191897;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2430462963"}